Details
Recent clinical trial findings reveal promising news for the community. A targeted treatment has been shown to rapidly and consistently lower the disease-causing protein levels that lead to amyloid deposits.
The study indicates that these reductions were reliable across a wide range of individuals, including people with hATTR-PN and ATTR-CM, regardless of age, sex, or disease severity.